绿脓杆菌MSHA菌毛株菌苗对恶性淋巴瘤的治疗及其机制初探

Role and Mechanism of PA-MSHA in the Treatment of Malignant Lymphoma

绿脓杆菌MSHA菌毛株菌苗是一种新型的微生物免疫调节剂，首次应用于恶性淋巴瘤化疗的辅助治疗。结果显示：在化疗同时进行菌苗治疗组其治疗有效率（95．56％）明显高于仅进行化疗的对照组（69．77％），而感染率（17．78％）则明显低于对照组（37．21％），P值均小于0．05。菌苗治疗组IL－2水平，NK细胞活性及CD4+／CD8+比值也明显高于对照组，且其抵抗多种不同菌属的革兰氏阴性杆菌抗体水平亦显著高于对照组，提示该菌苗是通过调整或增强患者自身细胞免疫或体液免疫水平，达到抗肿瘤．抗感染的功效。作者认为该菌苗是恶性淋巴瘤患者化疗的良好辅助药物。

The Pseudomonas aeruginosa with mannose sensitive hemagglutination pili (PA-MSHA), a new type of microbial immunoregulator was first used totreat patients with Hodgkin's disease or non-Hodgkin's lymphoma. The results showedthat the effective rate and infection rate were 95.56% and 17.78% respectively in patients group of PA-MSHA plus chemotherapy as compared to 69.77% and 37.21% respectively in the control group in which chemotherapy was given alone. The differencewas statistically significant (P＜0.05). Measurement of IL-2, the CD4+ /CD8+ ratio,the activity of natural killer cells and the titer of antibody of Ps. aeruginosa, E. coli, K.pneurnoniae and P. vugaris were all higher than those of the control group. These indicate that the vaccine of PA-MSHA might play an antitumor and anti-infections rolethrough regulating and enhancing the cellular immunity and humoral immunity. Theauthors believe that this immunoregulator is a good supplementary agent to chenaotherapy for patients with malignant lymphoma.